Case Studies

DiagnoSearch Life Sciences recently completed a Phase IIb trial in type II diabetic patients for a NASDAQ-listed pharma company based in the United States.

The study was a 90-day, multi-center, double-blind, randomized, add-on study to evaluate the safety and efficacy of low and high dose of oral insulin/4-CNAB tablets versus placebo in subjects with type II Diabetes Mellitus who have inadequate glycemic control with metformin monotherapy.